HC Wainwright Reaffirms Buy Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $11.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 50.27% from the stock’s current price.

Kamada Stock Performance

Kamada stock opened at $7.32 on Friday. Kamada has a 52 week low of $4.74 and a 52 week high of $7.96. The stock has a market capitalization of $420.75 million, a P/E ratio of 26.14 and a beta of 0.98. The stock has a fifty day moving average of $6.06 and a 200-day moving average of $5.67.

Institutional Investors Weigh In On Kamada

An institutional investor recently bought a new position in Kamada stock. Plato Investment Management Ltd bought a new stake in Kamada Ltd. (NASDAQ:KMDA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.